Posts

Next Gen Immuno-Oncology Congress, London

OracleBio will be attending the Next Gen Immuno-Oncology Congress, which takes place from the 13th to the 14th of March in London.

Next Gen Immuno-Oncology

OracleBio provides a range of digital pathology image analysis services that support pre-clinical and clinical Immuno-Oncology R&D. Using immunohistochemistry and immunoflourescence techniques, we are able to produce a variety of quantifiable results valuable to oncology research, such as immune cell number, immune cell co-localisation and spatial distribution within the tumor microenvironment. To find out more about OracleBio’s Immuno-Oncology services, please click here. 

The Next Gen Immuno-Oncology Congress brings together academics, researchers and scientists from research institutes, Biotech and Pharma companies, to discuss the growth of existing therapeutics and pave the way for emerging next generation therapeutics. To find out more about the congress, please click here. 

If you would like to find out more about OracleBio’s services, or if you wish to arrange a time to speak with OracleBio’s European Business Manager, Clíona MacSweeney, during the congress, please contact us. 

To keep up to date with all OracleBio news, please follow us on LinkedIn by clicking on the button below:

Immune Checkpoint Inhibitors Summit, Munich 2016

OracleBio will be attending the Annual Immune Checkpoint Inhibitors Europe Summit, which takes place from the 16th to the 18th of November in Munich, Germany.

immune checkpoint inhibitors logo

OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical immuno-oncology R&D and have generated data as part of immune checkpoint inhibitor studies. In one recently published study, we performed digital image analysis for quantification of CD8+T-cells in a mouse syngeneic model to demonstrate the potential of a checkpoint inhibitor combination therapy. OracleBio have generated case studies from this research, as well as other immune checkpoint inhibitor studies, and look forward to discussing this in greater detail at ICI Europe 2016.

Returning for the second year, Immune Checkpoint Inhibitors (ICI) Europe 2016 focuses on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations. Incorporating insights from industry leaders, the summit will deliver practical learning on what it takes to develop the next generation of ICI drugs, from pathway validation to clinical success. For more information on Immune Checkpoint Inhibitors (ICI) Europe 2016, please click here.

If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with OracleBio’s Chief Operations Officer John Waller during the conference, please contact us

john-waller1

Molecular Medicine Tri-Conference 2017

OracleBio data will be presented on a poster at the International Molecular Medicine TriConference, taking place in San Francisco on the 19th – 24th February.

TriConference Logo

The poster, made in collaboration with Asterand Bioscience, is titled ‘Content and Spatial Distribution Analysis of PD-L1 Positive Tumor Cells and CD8 Positive T-Cells within Multiplex IHC Stained NSCLC Tumor Tissue’.

Click here to view or download the poster

OracleBio provides a range of digital pathology services that support clinical and pre-clinical Pharmaceutical R&D. To find out more about Spatial Distribution Analysis or OracleBio’s services, please contact us.

The Molecular Medicine Tri-Conference brings together over 3,500 drug discovery and development professionals from around the world to discuss the latest insights on Discovery, Genomics, Diagnostics and Information Technology. For more details on the event, please click here.

Immune Checkpoint Inhibitors Conference, Boston

OracleBio will be attending the Immune Checkpoint Inhibitors Boston Conference, which runs from the 14th to the 16th of March 2017.

Immune Checkpoint Inhibitors Boston

OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical immuno-oncology R&D and have generated data as part of immune checkpoint inhibitor studies. In one recently published study, we performed digital image analysis for quantification of CD8+T-cells in a mouse syngeneic model to demonstrate the potential of a checkpoint inhibitor combination therapy. OracleBio’s Business Development Manager, Matt Gaffney, will be at ICI Boston to discuss this case study, as well as other immune checkpoint inhibitor studies, in more detail.

Returning for its 3rd year, ICI Boston 2017 address key issues in the immuno-oncology field and provides comprehensive insights into immune checkpoint development. The conference focuses on delivering maximum clinical benefit through immune checkpoint monotherapy and combinations, from pathway validation to clinical success. To find out more about ICI Boston, please click here.

If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with Matt during the conference, please contact us

To keep up to date with all OracleBio news, please follow us on LinkedIn by clicking on the button below:

Keystone Symposia

Keystone Symposia Injury, Inflammation and Fibrosis Conference

OracleBio data will be presented on a poster at the Keystone Symposia Injury, Inflammation and Fibrosis Conference, taking place 26th – 30th March 2017 in Snowbird, Utah.

Keystone Symposia

The poster, made in collaboration with Charles River and Grünenthal, is titled ‘Quantitative Image Analysis of Fibrotic Lesion Progression in the Mouse Bleomycin Model of Pulmonary Fibrosis’. It is Poster No. 3041 and will be presented during Poster Session 3, which runs from 7.30pm – 10pm on Wednesday 29th March.

Click here to view or download the poster

OracleBio provides a range of digital pathology services that support clinical and pre-clinical Pharmaceutical R&D. To find out more about Quantitative Image Analysis or OracleBio’s services, please contact us.

Keystone Symposia is a nonprofit organization that convenes open, peer-reviewed conferences across a broad range of the life sciences. This conference will bring together basic biologists and translational and clinical researchers to discuss core mechanisms underlying inflammation and fibrosis, to compare and contrast fibrotic diseases, preclinical models, the potential for regeneration and regression of fibrosis, and potential therapies. For more information on the conference, please click here. 

To keep up to date with all OracleBio news and events, please follow us on LinkedIn by clicking the button below:

Experimental Biology

Experimental Biology Meeting 2017

OracleBio data will be presented on a poster at the Experimental Biology Meeting 2017, which takes place 22nd – 26th April in Chicago.

Experimental Biology

The poster is titled ‘Whole Slide Quantitative Image Analysis can Demonstrate Bleomycin Induced Dose-Dependent Increases in Fibrotic Areas Within Histologically Stained Rat Lung Tissue’ and was produced in collaboration with Charles River.

The poster will be available to view or download from this page from the 22nd April

The annual Experimental Biology meeting brings together over 14,000 scientists from six societies to discuss the latest research impacting life sciences. Primary focus areas include anatomy, biochemistry and molecular biology, investigative pathology, nutrition, pharmacology, and physiology. To find out more about Experimental Biology, please click here

OracleBio provides a range of digital pathology services that support clinical and pre-clinical Pharmaceutical R&D. To find out more about Quantitative Image Analysis or OracleBio’s services, please contact us.

To keep up to date with all OracleBio news and events, please follow us on LinkedIn by clicking the button below:

 

American Thoracic Society Conference 2017

OracleBio will be exhibiting at the 2017 American Thoracic Society (ATS) Conference, which takes place from the 19th to the 24th of May in Washington D.C.

ATS Conference

OracleBio are pleased to have data presented on two posters at the conference:

Quantification of Differential Fibrotic Lesions by Image Analysis in the Mouse Bleomycin Model of Pulmonary Fibrosis
Tuesday 23rd May, 11.15am – 1.00pm
Fibrosis: Current and Future Approaches Session
Poster Board Number: P32
Produced in collaboration with Charles River and Grünenthal

Respiratory Function and Quantitative Measurement of Fibrosis in a Rat Model of Bleomycin-Induced Lung Fibrosis’
Tuesday 23rd May, 11.15am – 1:00pm
Fibrosis: Current and Future Approaches Session
Poster Board Number: P22
Produced in collaboration with Charles River

OracleBio’s US Business Development Manager, Matt Gaffney and Senior Project Manager, Mark Anderson will be at Booth 1349 throughout the conference.  If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with Mark and Matt during the event, please contact us.

The American Thoracic Society improves global health by advancing research, patient care and public health in pulmonary disease, critical illness and sleep disorders. The annual conference brings together over 16,000 clinicians, researchers and health care professionals to hear ground breaking research and experience hands-on training. To find out more about the ATS, please click here.

OracleBio provides a range of digital pathology services that support clinical and pre-clinical Pharmaceutical R&D. For more details on how our services can support your research, please click here. 

To keep up to date with all OracleBio news and events, please follow us on LinkedIn by clicking the button below:

 

American Association for Cancer Research (AACR) Annual Meeting 2017

OracleBio will be exhibiting at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), which takes place from the 1st to the 5th April in Washington D.C.

OracleBio are pleased to be presenting two posters at the conference:

‘Evaluation of ETS2101 and its combination with anti-mCTLA4 monoclonal antibody on CD4 and CD8 TILs in a subcutaneous colorectal cancer model of CT-26’
Sunday 2nd April, 2017 1pm – 5pm
Presenter: Lorcan Sherry, PhD, Chief Scientific Officer
Session: Tumor Microenvironment in Drug Development
Poster Section 7 | Poster Board 2
Produced in collaboration with E-Therapeutics

‘Utilizing multiplex chromogenic IHC and digital image analysis to evaluate immune cell content and spatial distribution within NSCLC tumor tissue’

Monday 3rd April, 2017 1pm – 5pm
Presenter: Lorcan Sherry, PhD, Chief Scientific Officer
Session: Tumor Microenvironment 3
Poster Section 43 | Poster Board 8
Produced in collaboration with Asterand Bioscience

OracleBio offers a range of digital pathology services to support pre-clinical and clinical oncology R&D. Using immunohistochemistry and immunoflourescence techniques, we are able to produce a variety of quantifiable results valuable to oncology research, such as immune cell number, immune cell co-localisation and spatial distribution within the tumor microenvironment. Click here to find out more information about how our services can support your oncology research.

The Annual Meeting of the AACR is in its 109th year and highlights the best cancer science and medicine from institutions from all over the world. To find out more about the AACR, please click here.

Matt Gaffney, OracleBio’s US Business Development Manager, along with our CSO, Lorcan Sherry, and Senior Project Manager, Mark Anderson will be at Booth 1363 throughout the meeting.  If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with Lorcan, Mark and Matt during the event, please contact us.

To keep up to date with all OracleBio news and events, follow us on LinkedIn by clicking the button below:

Tumour Models London

OracleBio will be attending the 6th Annual Tumour Models London Summit which takes place from the 5th to the 7th of December 2017.

OracleBio attend Tumour Models LondonThe Annual Tumour Models London Summit brings together individuals from pharma, biotech and academic institutions to share their discoveries and pre-clinical case studies that use in vivo, ex vivo and in vitro models. The summit will focus on immunotherapy, combination therapies and the very latest improvements in pre-clinical and translation imaging designed to improve the predictability and interpretation of model based research. To find out more about the event, please click here. 

OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical oncology R&D. We have experience working with both xenograft and syngeneic tumour models and have worked on immune checkpoint inhibitor studies in these models.  For more information on how our services can support your oncology research, please click here.

If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with OracleBio’s during the event, please contact us

 

Society for Immunotherapy of Cancer Conference

Immunotherapy-banner-2016

OracleBio’s Chief Scientific Officer Lorcan Sherry and Senior Project Manager Mark Anderson will be attending the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event will take place from the 9th to the 13th of November in Washington and is known to be one of the top destinations for scientific exchange, education and networking in the cancer immunotherapy community. The conference is expected to bring together more than 2,400 individuals from around the world to discuss the newest science, insights and innovation in the cancer immunotherapy field.

OracleBio is delighted to be exhibiting at the conference and will also be presenting a poster entitled; ‘Immune Cell Spatial Analysis on FoxP3 and CD8 Positive IHC Stained T Cells within the Tumor Microenvironment’. In this study, tumor tissue was immunohistochemically (IHC) dual labelled for FoxP3 (brown nuclear chromogen) and CD8 (red membrane chromogen). High resolution digital images of these samples were then analysed by OracleBio to quantify CD8 and FoxP3 immune cell relationships in terms of cell infiltration and cell-to-cell proximities within the tumor tissue microenvironment.

We will also be at exhibitor booth No. 337 throughout the conference and look forward to meeting you there to discuss how OracleBio can support your immuno-oncology projects using detailed quantitative image analysis.

OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical Oncology R&D studies. If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak to Lorcan or Mark during the congress, please contact us.

Mark   Lorcan